ValiRx Regulatory News (VAL)

Proactive Investors UK

Manchester One2One Investors Forum - June 26

Proactive Investors, the international financial news provider to one of the world's largest communities of sophisticated investors, is pleased to unveil the line-up for its Manchester One2One Investor Forum on June 26.

Presenting are three exciting growth companies: e-Therapeutics, (LON:ETX), ValiRx (LON:VAL) and Deltex Medical (LON:DEMG). Capsule descriptions of each company are supplied below.

The event will take place at The Midland Hotel, Peter Street, Manchester, at 6pm.

This is a rare opportunity to meet the management and quiz them on the prospects of their respective businesses.

It is a Dragon's Den-style format with each firm making a 20 minute presentation followed by a 10 minute Q&A session. This is then followed by a networking event afterwards at which there is the opportunity to chat informally to the people who run these companies.

Proactive Investors has hosted more than 300 forums worldwide. Investors were first introduced to the potential of e-Therapeutics, ValiRx and Deltex Medical through the Proactive Investors media network and meetings of this kind.

Managing director Craig Ribton said: "This is an opportunity to gain access to three companies that is only usually granted to large institutional shareholders. What we are doing is levelling the playing field for private investors, getting them closer to some of Britain's most exciting growth stories.

"The companies like the events because it enables them to address a very knowledgeable and well informed base of investors. This was certainly the case the last time we visited Manchester."

The events are completely free to attend. To avoid disappointment and for more information sign up today at www.proactiveinvestors.co.uk/events

Please join us at 5:45pm to get yourself a seat and to allow for a prompt 6:00pm start. Each company has approximately 30 minutes to give a short presentation and for Q&A. Followed by the 'Champagne Raffle' were 6 lucky guests will win a bottle each. The evening will end with a complimentary bar and an assortment of the finest hot & cold canapés, giving you the opportunity to speak with the directors and other investors

For more information on the event, contact Ruth Gemmell on +44 (0)207 989 0813 or events@proactiveinvestors.com 

For media enquiries, call Ian Lyall on 0207 264 3922

ABOUT PROACTIVE INVESTORS

Proactive Investors is recognised as the leading news portal for growth companies and has offices in London, New York, Toronto and Sydney. Annually more than 3 million people visit our sites. We have also organised more than 300 meet-the-management forums that have introduced investors to some of the market's most exciting investment stories.

COMPANY DESCRIPTIONS

ValiRx is at an exciting stage in its development as it prepares for first-in-man trials of its lead drug candidate VAL 201 for cancer. Initially, the target will be prostate cancer, but there may be the opportunity to broaden its scope. Initial results from the trial are due by the end of the year. ValiRx's plan is a smart one - to take VAL 201 along the value chain and part way through the clinical trial process before then finding a partner that will shoulder the financial and clinical risk that comes with later stage development of a drug. With us in Manchester will be chief executive Satu Vainikka.

With the share price up 23% since the end of May, you sense the tide could be turning for Deltex Medical, the inventor of the revolutionary CardioQ-ODM system. The device changes the way doctors care for surgical patients, allowing patients to recover faster and leave hospital sooner, and in better health, than they otherwise would do. In bald terms CardioQ has the potential to save cash-strapped healthcare providers such as the NHS huge amounts of money annually. Updating us on the progress will be finance director Paul Mitchell.

For e-Therapeutics, the Oxford and Newcastle-based pioneer of network pharmacology, the funding silver bullet was fired in March when it successfully concluded a £40mln cash call. The primary goal is to bankroll the development of cancer treatment ETS2101 through further trials, including a proof-of-concept phase II study in its lead indication of glioma, a type of brain tumour. Around £25mln has been earmarked to pursue the principal glioma indication, together with four to six additional solid tumour indications. Setting out ETX's roadmap will be chief financial officer Daniel Elger.